Sydney, June 9, 2026, 03:05 AEST
CSL Limited will resume trading on the ASX on Tuesday, with Friday’s jump to A$97.91 the most recent close. Shares climbed A$5.32, or 5.75%, in that session. The market was closed Monday for the King’s Birthday holiday—ASX listed June 8 as a non-settlement day.
CSL’s bounce stood out as the S&P/ASX 200 dropped 0.7% to 8,625.10 on Friday and lost 1.2% this week. Banks and miners drove most of the losses for Australia’s main large-cap index.
For CSL, it was more about sentiment than numbers. Shares were just 1.35% above the A$96.61 finish from a week ago, according to Intelligent Investor data, and remain down 59.29% so far this financial year.
CSL’s jump wasn’t the only action in healthcare. Cochlear rose 5.6%, ResMed added 4.3%, and Pro Medicus gained 4.0%, pointing to a swing into the sector, not just a single-name bounce.
CSL’s outlook after its May review is still a problem for the market. The company cut FY26 guidance to revenue of around US$15.2 billion and NPATA of about US$3.1 billion on a constant-currency basis. NPATA refers to net profit after tax before amortisation of acquired intangibles and big one-off items. Interim CEO Gordon Naylor said growth strategies are “working” but will “take longer than previously anticipated to materialise.” CSL has also warned of about US$5 billion in non-cash pre-tax impairments, or accounting writedowns, spread over FY26 and FY27.
So investors aren’t calling a bottom yet. CSL’s next full-year results aren’t due until Aug. 18, based on its May statement.
The pressure was already building before May. Back in October, Reuters said CSL held off on spinning off its Seqirus vaccine business and lowered its outlook after U.S. flu shot rates dropped more than expected. Chairman Brian McNamee called the collapse “remarkable” and said the company couldn’t see a floor in U.S. vaccination volumes. Reuters
CSL’s August plan called for as many as 3,000 layoffs, a possible spin-off of the Seqirus vaccine business, and aimed for yearly savings between US$500 million and US$550 million in three years. Craig Sidney, senior investment adviser at Shaw and Partners, told Reuters that job cuts are “normally a positive thing” but said the move might slow earnings growth. Reuters
First up this week is a basic test: do buyers hold last Friday’s bounce as cash trading starts again? There wasn’t a session on Monday, so ASX hasn’t seen new price action in the last day.
But the trade could flip fast. If Friday was only a holiday week move into weak healthcare names, or if U.S. immunoglobulin stocks, China albumin prices, and Vifor writedowns keep weighing on earnings, CSL might lose the rally just as quickly.
This is not a turnaround story yet. The battered index heavyweight is catching a strong bounce, but the market still has another vote ahead.
